BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 37444397)

  • 1. Biomarker Discovery in Rare Malignancies: Development of a miRNA Signature for RDEB-cSCC.
    Zauner R; Wimmer M; Atzmueller S; Proell J; Niklas N; Ablinger M; Reisenberger M; Lettner T; Illmer J; Dorfer S; Koller U; Guttmann-Gruber C; Hofbauer JP; Bauer JW; Wally V
    Cancers (Basel); 2023 Jun; 15(13):. PubMed ID: 37444397
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metformin shows anti-neoplastic properties by inhibition of oxidative phosphorylation and glycolysis in epidermolysis bullosa-associated aggressive cutaneous squamous cell carcinoma.
    Welponer T; Weber DD; Trattner L; Tockner B; Aminzadeh-Gohari S; Leb-Reichl V; Kaufmann A; Zauner R; Wimmer M; Wally V; Felder TK; Strunk D; Koller U; Bauer JW; Kofler B; Guttmann-Gruber C; Piñon Hofbauer J
    J Eur Acad Dermatol Venereol; 2024 Jan; 38(1):112-123. PubMed ID: 37669776
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reprogramming and Differentiation of Cutaneous Squamous Cell Carcinoma Cells in Recessive Dystrophic Epidermolysis Bullosa.
    Rami A; Łaczmański Ł; Jacków-Nowicka J; Jacków J
    Int J Mol Sci; 2020 Dec; 22(1):. PubMed ID: 33383666
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune Disregulation in Cutaneous Squamous Cell Carcinoma of Patients with Recessive Dystrophic Epidermolysis Bullosa: A Single Pilot Study.
    Filoni A; Cicco G; Cazzato G; Bosco A; Lospalluti L; Tucci M; Cimmino A; Foti C; Marzullo A; Bonamonte D
    Life (Basel); 2022 Jan; 12(2):. PubMed ID: 35207500
    [TBL] [Abstract][Full Text] [Related]  

  • 5. APOBEC mutation drives early-onset squamous cell carcinomas in recessive dystrophic epidermolysis bullosa.
    Cho RJ; Alexandrov LB; den Breems NY; Atanasova VS; Farshchian M; Purdom E; Nguyen TN; Coarfa C; Rajapakshe K; Prisco M; Sahu J; Tassone P; Greenawalt EJ; Collisson EA; Wu W; Yao H; Su X; Guttmann-Gruber C; Hofbauer JP; Hashmi R; Fuentes I; Benz SC; Golovato J; Ehli EA; Davis CM; Davies GE; Covington KR; Murrell DF; Salas-Alanis JC; Palisson F; Bruckner AL; Robinson W; Has C; Bruckner-Tuderman L; Titeux M; Jonkman MF; Rashidghamat E; Lwin SM; Mellerio JE; McGrath JA; Bauer JW; Hovnanian A; Tsai KY; South AP
    Sci Transl Med; 2018 Aug; 10(455):. PubMed ID: 30135250
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MicroRNA-200b-mediated reversion of a spectrum of epithelial-to-mesenchymal transition states in recessive dystrophic epidermolysis bullosa squamous cell carcinomas.
    Illmer J; Zauner R; Piñón Hofbauer J; Wimmer M; Gruner S; Ablinger M; Bischof J; Dorfer S; Hainzl S; Tober V; Bergson S; Sarig O; Samuelov L; Guttmann-Gruber C; Shalom-Feuerstein R; Sprecher E; Koller U; Laimer M; Bauer JW; Wally V
    Br J Dermatol; 2023 Dec; 190(1):80-93. PubMed ID: 37681509
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Update on the pathogenesis of squamous cell carcinoma development in recessive dystrophic epidermolysis bullosa.
    Kim M; Murrell DF
    Eur J Dermatol; 2015 Apr; 25 Suppl 1():30-2. PubMed ID: 26083672
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of tissue damage, extracellular matrix remodeling and bacterial challenge as common mechanisms associated with high-risk cutaneous squamous cell carcinomas.
    Föll MC; Fahrner M; Gretzmeier C; Thoma K; Biniossek ML; Kiritsi D; Meiss F; Schilling O; Nyström A; Kern JS
    Matrix Biol; 2018 Mar; 66():1-21. PubMed ID: 29158163
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epidermolysis bullosa and the risk of life-threatening cancers: the National EB Registry experience, 1986-2006.
    Fine JD; Johnson LB; Weiner M; Li KP; Suchindran C
    J Am Acad Dermatol; 2009 Feb; 60(2):203-11. PubMed ID: 19026465
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fibroblast-derived dermal matrix drives development of aggressive cutaneous squamous cell carcinoma in patients with recessive dystrophic epidermolysis bullosa.
    Ng YZ; Pourreyron C; Salas-Alanis JC; Dayal JH; Cepeda-Valdes R; Yan W; Wright S; Chen M; Fine JD; Hogg FJ; McGrath JA; Murrell DF; Leigh IM; Lane EB; South AP
    Cancer Res; 2012 Jul; 72(14):3522-34. PubMed ID: 22564523
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Heterogeneous addiction to transforming growth factor-beta signalling in recessive dystrophic epidermolysis bullosa-associated cutaneous squamous cell carcinoma.
    Dayal JHS; Mason SM; Salas-Alanis JC; McGrath JA; Taylor RG; Mellerio JE; Blyth K; South AP; Inman GJ
    Br J Dermatol; 2021 Apr; 184(4):697-708. PubMed ID: 32726455
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Successful use of immunotherapy to treat advanced cutaneous squamous cell carcinoma in recessive dystrophic epidermolysis bullosa.
    Duong T; Wong D; Barrett A; Price H
    BMJ Case Rep; 2021 Feb; 14(2):. PubMed ID: 33637494
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of Rigosertib for the Treatment of Recessive Dystrophic Epidermolysis Bullosa-Associated Squamous Cell Carcinoma.
    Atanasova VS; Pourreyron C; Farshchian M; Lawler M; Brown CA; Watt SA; Wright S; Warkala M; Guttmann-Gruber C; Hofbauer JP; Fuentes I; Prisco M; Rashidghamat E; Has C; Salas-Alanis JC; Palisson F; Hovnanian A; McGrath JA; Mellerio JE; Bauer JW; South AP
    Clin Cancer Res; 2019 Jun; 25(11):3384-3391. PubMed ID: 30846478
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transformation-specific matrix metalloproteinases (MMP)-7 and MMP-13 are expressed by tumour cells in epidermolysis bullosa-associated squamous cell carcinomas.
    Kivisaari AK; Kallajoki M; Mirtti T; McGrath JA; Bauer JW; Weber F; Königová R; Sawamura D; Sato-Matsumura KC; Shimizu H; Csikós M; Sinemus K; Beckert W; Kähäri VM
    Br J Dermatol; 2008 Apr; 158(4):778-85. PubMed ID: 18284387
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TGFβ-signaling in squamous cell carcinoma occurring in recessive dystrophic epidermolysis bullosa.
    Knaup J; Gruber C; Krammer B; Ziegler V; Bauer J; Verwanger T
    Anal Cell Pathol (Amst); 2011; 34(6):339-53. PubMed ID: 22002724
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of transforming growth factor-β1 in recessive dystrophic epidermolysis bullosa squamous cell carcinoma.
    Twaroski K; Chen W; Pickett-Leonard M; Tolar J
    Exp Dermatol; 2021 May; 30(5):664-675. PubMed ID: 33595864
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Variable Outcome of Immunotherapy in Advanced Multiple Cutaneous Squamous Cell Carcinomas in Two Patients with Recessive Dystrophic Epidermolysis Bullosa.
    Trefzer L; Hess ME; Scholten L; Technau-Hafsi K; Meiss F; Boerries M; Has C; Rafei-Shamsabadi D
    Acta Derm Venereol; 2023 Jun; 103():adv4870. PubMed ID: 37338146
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MicroRNA-145-5p regulates fibrotic features of recessive dystrophic epidermolysis bullosa skin fibroblasts.
    Condorelli AG; Logli E; Cianfarani F; Teson M; Diociaiuti A; El Hachem M; Zambruno G; Castiglia D; Odorisio T
    Br J Dermatol; 2019 Nov; 181(5):1017-1027. PubMed ID: 30816994
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A cancer stem cell-like phenotype is associated with miR-10b expression in aggressive squamous cell carcinomas.
    Wimmer M; Zauner R; Ablinger M; Piñón-Hofbauer J; Guttmann-Gruber C; Reisenberger M; Lettner T; Niklas N; Proell J; Sajinovic M; De Souza P; Hainzl S; Kocher T; Murauer EM; Bauer JW; Strunk D; Reichelt J; Mellick AS; Wally V
    Cell Commun Signal; 2020 Apr; 18(1):61. PubMed ID: 32276641
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Involvement of p53 and p16 tumor suppressor genes in recessive dystrophic epidermolysis bullosa-associated squamous cell carcinoma.
    Arbiser JL; Fan CY; Su X; Van Emburgh BO; Cerimele F; Miller MS; Harvell J; Marinkovich MP
    J Invest Dermatol; 2004 Oct; 123(4):788-90. PubMed ID: 15373786
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.